CASE REPORT

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation

Karam Khaddour1, Ryan C. Fields2,3, Michael Anstas4, Ilana S. Rosman5,6 and George Anstas1,3*

Abstract

Background: Cutaneous malignancies are rare complications of Lynch syndrome and can include Muir-Torre and Turcot syndromes that are associated with sebaceous gland tumors and keratoacanthomas. The incidence and clinical course of cutaneous squamous cell carcinoma have not been well documented in Lynch syndrome due to its rarity.

Case presentation: A 49-year male presented with an enlarging groin skin lesion that was biopsed and demonstrated cutaneous squamous cell carcinoma for which he underwent a surgical resection. The patient experienced later a recurrence of cutaneous squamous cell carcinoma around the resected margins. Next generation sequencing of tumor tissue revealed mutations in MSH6 and MLH1, in addition to high microsatellite instability. The patient underwent pembrolizumab treatment with complete resolution of the cutaneous lesion in the groin, but subsequently developed a new mass in the right antecubital fossa shortly after discontinuation of pembrolizumab. Repeat biopsy of the antecubital fossa lesion revealed a recurrence of cutaneous squamous cell carcinoma. Germline mutation testing revealed MLH1 mutation, compatible with Lynch syndrome, and the patient restarted pembrolizumab which was associated with a complete response. The patient was referred for genetic counseling and cancer screening.

Conclusions: Cutaneous squamous cell carcinoma, although rare, can be the initial presenting symptom in patients with Lynch syndrome. This association has been described in patients with germline mutations in MLH1. Lynch syndrome should be considered when evaluating young patients presenting with recurrent cutaneous squamous cell carcinoma with positive family history of malignancy and/or without any identifiable risk factors for skin cancers, including those with a durable and rapid response to immunotherapy.

Keywords: Lynch syndrome, Cutaneous squamous cell carcinoma, Germline mutation, MLH1, Pembrolizumab, Microsatellite instability

* Correspondence: gansstas@wustl.edu
1Department of Medicine, Division of Medical Oncology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA
2Alvin J. Siteman Cancer Center, St. Louis, MO, USA
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Lynch syndrome (LS) is an autosomal dominant disorder that was first described by Warthin in a family in Michigan state with a high susceptibility to develop cancers. This was further described in detail by Lynch in 1971. The etiology of LS involves a germline mutation in one of the DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2) or the EPCAM gene [1]. The clinical suspicion of LS is based on pre-defined criteria (Amsterdam Criteria) which focuses on family history of cancers in different generations and at an early age. Patients with LS are at an increased risk for developing a variety of cancers including cancers of the colon, uterus, small bowel, stomach, kidney, ureter, biliary tract, ovaries, brain and pancreas [2].

Skin tumors are uncommon manifestations of LS and have been described in the form of Muir–Torre syndrome which is associated with a higher risk of sebaceous adenoma, sebaceous carcinoma or keratoacanthoma [3]. Cutaneous squamous cell carcinomas (cSCC) are rare in patients with LS, and there is paucity of literature describing their incidence and clinical course in this patient population. Here, we report a young patient who presented with advanced cSCC which was complicated by multiple recurrences in different locations, and was later diagnosed with LS due to MLH1 germline mutation.

Case presentation
A 49-year-old male without significant past medical history presented after noticing a small raised papule in the left groin in 2016 that he initially thought to be a spider bite. He stated that over the subsequent year, the lesion grew in size and became more red and foul smelling. He was seen in multiple walk-in clinics and completed multiple courses of antibiotics. These interventions did not improve the lesion as it did continue to become more erythematous, painful, and ulcerated. This lesion was evaluated by plastic surgery service with subsequent biopsy in 2017 which demonstrated well differentiated squamous cell carcinoma (SCC). A staging computed tomography (CT) was performed which showed a 7.5 × 1.8 cm soft tissue mass on the left lower abdominal wall with ulceration and overlying skin thickening without areas of regionally advanced or metastatic disease. On further evaluation, the patient denied any prolonged sun exposure, radiation exposure, or history of immunosuppression. HIV and immune competence tests were normal. As part of his medical history, questioning revealed a family history of ovarian cancer in his mother (diagnosed in her late 50s) and colon cancer in his maternal uncle (unknown age at diagnosis).

The patient underwent a radical resection of the mass, resulting in a 15 cm diameter resection, and bilateral inguinal sentinel lymph node biopsies (SLNB). This demonstrated a 9 cm squamous cell carcinoma, moderately to poorly differentiated, and invasive to a depth of 16 mm with perineural invasion. The surgical margins were negative without nodal disease on SLNB. His wound was then closed with a skin graft.

After 7 months, the patient noted a new growth around his prior skin graft. Biopsy demonstrated recurrent cutaneous squamous cell carcinoma (Fig. 1). Tumor analysis with next generation sequencing (NGS) showed high tumor mutational burden (TMB) of 46 mutations per mega base and high microsatellite instability (MSI-H). There were multiple mutations including MSH6 (F1088fs*5) and MLH1 (loss of exon 4–8). Programmed death-ligand 1 (PD-L1) analysis by immunohistochemistry demonstrated PD-L1 expression of 30% on the tumor and 10% on the tumor-infiltrating immune cells. CT scan showed bulky disease in left lower pelvis extending to the thigh with invasion to the adductor muscles and abutment of penile shaft (Fig. 2).

Due to the locally advanced nature of the tumor and (MSI-H), the patient was started on pembrolizumab 200 mg intravenously every three weeks and this was continued for 2 years. The patient achieved complete clinical and radiographic response after 4 cycles of therapy and maintained that response throughout his course of treatment (Fig. 2). Three months after discontinuation of pembrolizumab, the patient developed a small nodule in the right antecubital fossa (Fig. 3) and biopsy showed a well differentiated SCC of the skin with PD-L1 expression <1% (Fig. 1). Given the unusual recurrence of cSCC in a new location and the presence of MLH1 and MSH6 mutations in the tumor with an unclear family history of cancer, germline genetic testing for hereditary cancers was performed after discussion with the patient. This revealed a germline mutation in MLH1 (EX4_8del).

Staging imaging with CT showed no sites of metastatic disease, and the right antecubital lesion was deemed recurrent cSCC. During workup, the lesion progressed very rapidly within 1 month (Fig. 3). We restarted pembrolizumab urgently with rapid observed response after 2 cycles of therapy (Fig. 3). Currently, the patient has been treated for 5 months and maintains his clinical response. The patient was referred for genetic counseling and further evaluation including appropriate cancer screening.

Discussion and conclusion
Lynch syndrome (LS) is a common inherited disorder involving germline mutation in DNA mismatch repair (MMR) genes [1]. Although the main malignant phenotypic manifestation of LS is colorectal cancer, patients are at increased risk of other visceral tumors such as gastrointestinal, gynecological and genitourinary malignancies [2]. Skin tumors in the context of LS are rare with the most recognized variant being Muir-Torre and...
Turcot syndromes which can be associated with skin tumors including sebaceous gland tumors and keratoacanthoma [3]. Of interest, the incidence of cutaneous squamous cell carcinoma (cSCC) is very rare and has not been described in detail in the literature. Our report demonstrates the potential risk for developing cSCC in patients with LS and provides an insight into the clinical course of the disease in one patient. In a large prospective cohort of 1942 patients with germ-line mutations and documented LS, there were only 12 cases with skin cancer including epithelial and sebaceous gland invasive cancer [4]. Our reports highlight a case of a young patient who did not have a history of LS and presented with cSCC in a non-sun exposed area (groin). He did
not have risk factors such as immunosuppression or pro-
longed sun exposure. The patient had a recurrence of
his disease after surgical resection with high MSI de-
tected on NGS of tumor tissue, which prompted treat-
ment with pembrolizumab [5]. However, there was a
rapid recurrence of cSCC in a different location (arm),
which was observed after discontinuation of pembrolizu-
mab. The presence of mutations in MSH6 and MLH1
with high tumor mutational burden prompted further
review of patient’s family history and germline mutation
testing, which revealed MLH1 germline mutation con-
istent with LS. Interestingly, we identified two different
mutations by NGS on tumor tissue (MLH1 and MSH6),
and later the patient was found to have MLH1 germline
mutation. We believe that MSH6 mutation which was
detected on tissue specimen was a somatic mutation, as
it has been described to be present sporadically or in as-
association with different Lynch germline mutations [6].

Our case emphasizes the importance of considering
hereditary cancer syndromes such as LS in young pa-
tients who present with cSCC, and do not display risk
factors such as immunosuppression or substantial sun
and/or radiation exposure. Some reports described pa-
tients with LS with MLH1 and MSH2 germline muta-
tions, who developed cSCC and are summarized in
Table 1 [2, 7, 8]. Moreover, there has been reports of pa-
tients with cSCC who had MLH1 mutation in their
tumor on NGS but there was no consideration of genetic
counseling or germline testing in those cases [9]. An-
other report described a patient with cSCC who had
mutations in MSH2, MLH1 and PMS2 with history of
LS but with a negative germline mutation testing [10].
Our report, combined with previous observations, sug-
ject the importance of careful examination of patient’s
family history and high index of suspicion of hereditary
cancer syndromes when patients present with cSCC
without known risk factors, especially in young patients
as this could be the initial presentation of hereditary dis-
ese such as LS. The consideration of germline mutation
testing is reasonable in such cases after discussion
with patients about risks and benefits of germline testing
and proper genetic counseling. Similarly, the occurrence
of cSCC in non- sun exposed skin areas and the recur-
rent pattern should prompt further consideration of

| Author, Year | Age | Gender | Germline Mutation | Other Malignancies | Treatment of cSCC | Outcome of cSCC |
|--------------|-----|--------|-------------------|-------------------|-----------------|----------------|
| Sorscher S, 2015 [7] | 54 | Male | MLH1 (1772del4) | Colon Cancer | Resection | N/A |
| Adan F et al. 2019 [8] | 33 | Female | MSH2 (c.551del p.Phe184Serfs*30) | None (Hyperplastic colon polyp) | Resection | N/A |
| Latham A et al. 2019 [2] | 69 | N/A | MSH2 (c.1046C > G; p.Pro349Arg) | Colon, Prostate, Urothelial | N/A | N/A |
| Latham A et al. 2019 [2] | 55 | N/A | MSH2 (c.1906G > C; p.Ala63Pro) | Colon, Urothelial | N/A | N/A |
| Latham A et al. 2019 [2] | 62 | N/A | MSH2 (c.1216C > T; p.Arg406*) | Colon, Prostate | N/A | N/A |

cSCC Cytoma squamous cell carcinoma, N/A not available
hereditary syndromes including LS. Pembrolizumab, an immune checkpoint inhibitor, has shown efficacy in tumors harboring high MSI, such as the case of our patient, and was also approved recently for the treatment of cSCC [11, 12]. The trial protocols used pembrolizumab until disease progression or high-grade adverse event. In our patient, we observed a rapid response of cSCC in the groin region to pembrolizumab, however, there was a rapid progression of cSCC in a different skin site within 3 months after stopping pembrolizumab. Moreover, restarting the medication resulted in a rapid and sustained response which favors a strategy of continuous administration in such patients.

In conclusion, we report a young 49-year-old patient who presented with cutaneous squamous cell carcinoma harboring germline mutation in MLH1 which was compatible with Lynch syndrome. This report suggests the following: 1) cSCC, although rare, can be the initial presenting manifestation of LS; 2) LS should be considered in patients who present with unexplained cSCC with a positive family history for cancer and without known risk factors for skin cancer, especially in younger patients; 3) discontinuation of pembrolizumab in patients with LS and cSCC could be associated with a rapid recurrence of cSCC.

Abbreviations
LS: Lynch syndrome; PD-1: Programmed death-1; PD-L1: Programmed death-ligand 1; cSCC: Cutaneous squamous cell carcinoma; MMR: Mismatch repair; CT: Computed tomography

Acknowledgments
Not applicable.

Authors’ contributions
KK wrote the manuscript, performed literature search and created Table 1. MA provided review of the manuscript. RF performed surgery on the patient. ISR provided histopathological images. GA reviewed the manuscript and supervised the work. All co-authors read the final version of the manuscript and approved it.

Funding
There was no finding for this project.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
A written consent has been obtained from the patient prior to publication. A copy of the consent has been provided to the editorial office.

Competing interests
KK has nothing to disclose. RF has nothing to disclose. MA has nothing to disclose. ISR has nothing to disclose. GA has nothing to disclose.

Author details
1Department of Medicine, Division of Medical Oncology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. 2Section of Surgical Oncology, Department of Surgery, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. 3Alvin J. Siteman Cancer Center, St. Louis, MO, USA. 4Cedars Sinai Health System, Division of Gastroenterology, Los Angeles, California, USA. 5Division of Dermatology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. *Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.

Received: 28 July 2020 Accepted: 10 November 2020 Published online: 16 November 2020

References
1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919–32. https://doi.org/10.1056/NEJMoa022422 PMID: 12621137.

2. Latham A, Srivasan P, Knel Y, Shia J, Bandalamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gaut M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vlaji J, Mulherrige S, Galle J, Dickson MA, Jangigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunas D, Varghese AM, Bajorin D, Carlo M, Caddeo K, Walsh MF, Weiser M, Aguilar JG, Kilmarst DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Ofrit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019;37(4):286–95. https://doi.org/10.1200/JCO.2018.02828 Epub 2018 Oct 30. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942. PMID: 30376427; PMCID: PMC6553803.

3. South CD, Hampel H, Comerras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100(4):277–81. https://doi.org/10.1093/jnci/djm291 Epub 2008 Feb 12. PMID: 18270343.

4. Moller P, Seppälä T, Bernstein I, Hollins-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hoving E, Radlaand EA, Tharmanathan K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Laloo L, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkenon-Sinisalo L, Frayling IM, Plazer JP, Pylvainen K, Sampson JR, Capella G, Mecklin JP, Möislein G, Mallorca Group (http://mallorca-group.eu). Cancer incidence and survival in Lynch syndrome patients receiving colonscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464–72. https://doi.org/10.1136/gutjnl-2015-309675 Epub 2015 Dec 9. PMID: 26557901; PMCID: PMC5534760.

5. Le DT UJN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Lahneru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocera TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bajjje F, Huebner T, Hubban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Comish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596 Epub 2015 May 30. PMID: 26028255; PMCID: PMC4481136.

6. Salvador MJ, Truelson MR, Mason C, Souders B, LaDuca H, Dougall B, Black WH, Fulk K, Profato J, Gutierrez S, Jasperson K, Tippin-Davis B, Lu HM, Gray P, Shah S, Chao EC, Graharmani N, Landwerk M, Gau CL, Chen D, Pronold M. Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process. J Clin Oncol. 2019;37(1):12. https://doi.org/10.1200/JCO.18.00283 Epub 2018 Oct 30. PMID: 30209270; PMCID: PMC6494248.

7. Concher S. A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch syndrome. Hered Cancer Clin Pract. 2015;13(1):12. https://doi.org/10.1186/s13053-015-0033-2 PMID: 25995776; PMCID: PMC4438563.

8. Adan F, Crijns MB, Dekker E, Bastaainen BAJ, Lapid O, Snaebjornsson P, Rosenberg EH, van Leerdam ME, Bekkenk MW. A squamous cell carcinoma in a young woman with Lynch syndrome. Famial Cancer. 2019;18(2):193–6. https://doi.org/10.1007/s10689-018-00113-5 PMID: 30560308.

9. Assam JH, Powell S, Spanos WC. Unsectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to Programmed Cell Death Protein 1 Inhibitor Therapy. Clin Skin Cancer. 2016;11(1):26–9. https://doi.org/10.1200/JCSS.2016.11.001 Epub 2016 Nov 23. PMID: 29933502; PMCID: PMC5766284.

10. Alsukait S, Almohsen Z, Alqarawi S, Aliaf F. Cutaneous squamous cell carcinoma in a patient with Lynch syndrome. Indian J Dermatol Venereol Leprol. 2020;86(4):407–9.

11. Le DT KTW, Van Cutsen E, Geva R, Jäger D, Hara H, Burge M, Oneil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Ah-Battan SE, Boland
PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9. https://doi.org/10.1200/JCO.19.02107 Epub 2019 Nov 14. PMID: 31725351; PMCID: PMC7031608.

12. Pembrolizumab: US Food and Drug Administration Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s068lbl.pdf (Accessed 17 July 2020), no abstract available.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.